• Pain intensifies for AbbVie as it slashes 178 jobs from Stemcentrx fiercebiotech
    March 29, 2019
    It was a $6 billion deal that was meant to help bolster AbbVie’s pipeline and help wean the biopharma off its Humira reliance, but Stemcentrx has proven to be a major thorn in its side. Now, the time has come to start digging it out.
PharmaSources Customer Service